Nippon Shinyaku has received marketing approval in Japan for Viltepso, a Morpholino targeting human dystrophin exon 53 for treatment of some mutations causing Duchenne muscular dystrophy. https://www.nippon-shinyaku.co.jp/file/download.php?file_id=2965
- Home
-
Products and Applications
-
Morpholino Antisense Oligos
- Why Morpholinos?
- Optimal Target Choice
- Methods/Protocols
- Morpholino Products and Properties
- End Modifications and Controls
- Blocking miRNAs
- Blocking Localization Elements of mRNA
- Modify poly-A Tailing
- Other targets: ncRNA, repeat elements, etc.
- External guides for use with RNase P
- Diagnostics
- Uses for Pretargeting & Crosslinking
- Therapeutics
- Bacteria Applications
- Protist Applications
- Insect Applications
-
Morpholino Antisense Oligos
- Ordering
- Customer Support
- Morpholino Publications Database
- FAQ
- About Us
- Contact Us
Add new comment